PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine
Open Access
- 3 May 2014
- journal article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 19
Abstract
Trivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections. However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of protection. Since the respiratory tract is the main site of influenza replications, a vaccine that triggers mucosal immunity in this region can potentially improve protection against this disease. Recently, PapMV nanoparticles used as an adjuvant in a formulation with TIV administered by the subcutaneous route have shown improving the immune response directed to the TIV and protection against an influenza challenge.Keywords
This publication has 18 references indexed in Scilit:
- Nanoparticle Adjuvant Sensing by TLR7 Enhances CD8+ T Cell–Mediated Protection from Listeria Monocytogenes InfectionThe Journal of Immunology, 2014
- Improvement of the Trivalent Inactivated Flu Vaccine Using PapMV NanoparticlesPLOS ONE, 2011
- Defending the mucosa: adjuvant and carrier formulations for mucosal immunityCurrent Opinion in Immunology, 2011
- Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus ClearanceJournal of Virology, 2011
- Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza VirusThe Journal of Immunology, 2011
- A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illnessVaccine, 2011
- Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere seasonVaccine, 2010
- What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens?The Journal of Immunology, 2009
- A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza VirusThe Journal of Immunology, 2008
- Immunization against Influenza: Comparison of Various Topical and Parenteral Regimens Containing Inactivated and/or Live Attenuated Vaccines in Healthy AdultsThe Journal of Infectious Diseases, 2001